Across TCGA pan-cancer cohorts, MAPK6P4 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated MAPK6P4 data layer.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MAPK6P4 RNA is associated with better overall survival. In most high-consensus cancer types, elevated MAPK6P4 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.
HNSC, BLCA, and STAD are the cancer types where MAPK6P4 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.